Trials / Unknown
UnknownNCT01645293
Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Patients with cutaneous CD30 positive lymphoma will receive systemical and topical treatment with their own genetically modified T cells. Treatment evaluation consists of assessment of safety and preliminary evidence of response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Genetically modified T cells # 1138 |
Timeline
- First posted
- 2012-07-20
- Last updated
- 2012-07-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01645293. Inclusion in this directory is not an endorsement.